久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂博生物技術(shù)有限公司
   
     
您當(dāng)前的位置: 網(wǎng)站首頁 > 產(chǎn)品展廳 >重組蛋白 >Recombinant Human SEC22B Protein, N-His
Recombinant Human SEC22B Protein, N-His
  • 品牌:AntibodySystem
  • 產(chǎn)地:France
  • 貨號(hào):YHB18801
  • 價(jià)格: ¥1880/支
  • 發(fā)布日期: 2024-05-31
  • 更新日期: 2024-10-24
產(chǎn)品詳請(qǐng)
產(chǎn)地 France
品牌 AntibodySystem
貨號(hào) YHB18801
用途 僅用于科研
包裝規(guī)格 100 μg
純度 0.95%
CAS編號(hào)
是否進(jìn)口

Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.

AntibodySystem由具有30多年蛋白抗體開發(fā)經(jīng)驗(yàn)的專家創(chuàng)立于法國,專注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國斯特拉斯堡市。AntibodySystem自主開發(fā)了高效、高產(chǎn)的真核重組表達(dá)系統(tǒng),利用該系統(tǒng)生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點(diǎn)蛋白以及對(duì)照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。


如果您對(duì)我們的產(chǎn)品感興趣,請(qǐng)聯(lián)系027-65279366或17736698252(同微信)

以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品說明書為準(zhǔn)

 

 


 

 

聯(lián)系方式
手機(jī):18162686757
微信掃一掃
灵武市| 贺兰县| 阿鲁科尔沁旗| 榆树市| 息烽县| 扶沟县| 临颍县| 泰来县| 衡山县| 濉溪县| 新乡县| 建平县| 婺源县| 隆昌县| 南和县| 灵山县| 临漳县| 万盛区| 海安县| 蕲春县| 永定县| 姜堰市| 临泉县| 南安市| 建平县| 胶州市| 万全县| 泰安市| 桐柏县| 潮安县| 呼伦贝尔市| 马龙县| 彰化县| 开原市| 海林市| 宁晋县| 会宁县| 封开县| 滨海县| 郓城县| 阜新|